Merck KGaA Could Benefit From Bavencio Sales Growth Until 2024
After Pfizer Alliance Exit
Executive Summary
While Q1 earnings were nothing exciting, the German major highlighted that Pfizer’s decisions to return to the rights to Bavencio would boost performance in the near term, although competition from Seagen is on the horizon.